Human Genome (HGSI) SUbmits BLA to U.S. FDA for BENLYSTA SLE Treatment

June 10, 2010 6:49 AM EDT Send to a Friend
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login